Jonathan Chang
Stock Analyst at Leerink Partners
(0.63)
# 4,080
Out of 5,090 analysts
81
Total ratings
30.67%
Success rate
-19.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $10.50 | +23.87% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $19.98 | +275.38% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $32.03 | -15.70% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $40.24 | +83.90% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $22.03 | -50.07% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $11.75 | +334.23% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $5.89 | +1,173.34% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.19 | +595.41% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $78.51 | -61.79% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.38 | +769.57% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $27.42 | +1,176.44% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $12.18 | +113.46% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $12.02 | +132.95% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $18.05 | +193.63% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $10.50
Upside: +23.87%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $19.98
Upside: +275.38%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $32.03
Upside: -15.70%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $40.24
Upside: +83.90%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $22.03
Upside: -50.07%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $11.75
Upside: +334.23%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $5.89
Upside: +1,173.34%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.19
Upside: +595.41%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $78.51
Upside: -61.79%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.38
Upside: +769.57%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $27.42
Upside: +1,176.44%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $12.18
Upside: +113.46%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $12.02
Upside: +132.95%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $18.05
Upside: +193.63%